[Chloroquine influence on lipid metabolism and selected laboratory parameters].
Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease with complex pathogenesis, various clinical presentation and chronic course with relapses. Mode of treatment depends on the disease activity and kind of internal organ involvement. In most cases clinical remission could be obtained after antimalarials, nonsteroidal anti-inflammatory drugs, corticosteroids, and photoprotection use. Despite the approved antimalarials therapeutic value, the mechanisms by which they provide benefit in lupus, patients are not fully understood. Literature data indicate that they can influence lipid metabolism. The aim of the performed study was the objective evaluation of the influence of 3-month chloroquine treatment (Arechin, 250 mg/day) on lipid metabolism and selected laboratory parameters. In 34 patients with SLE clinical and laboratory evaluation was performed twice, before and after 3-month treatment. After 3 months significantly lower total cholesterol level was observed (mean value 184.91 mg%, 165.26 mg%, p < 0.001). Also LDL level was evidently lowered (111.27 mg%, 99.25 mg%). Similar tendency was noticed in triglycerides, which level after 3 months decreased from the average 152.38 mg% to 104.97 mg%, p < 0.001. Moreover the lowering of sedimentation rate, increasing hemoglobin level and lengthening coagulation time was perceived. The results of the study indicate the influence of chloroquine on decreasing of the disease activity, its anti-inflammatory properties and mainly the drug impact on lipid metabolism. Not only does antimalarials treatment reduce the risk of atherosclerosis development but it also minimizes corticosteroids side effects, which are considered to be the basic medication in lupus patients.
Klinika Dermatologii i Wenerologii, Uniwersytetu Medycznego w Lodzi. wozniacka@bmp.net.pl
Anna
A
Woźniacka
Aleksandra
A
Lesiak
Janusz
J
Smigielski
Anna
A
Sysa-Jedrzejowska
D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D001799:Blood Sedimentation / Q000187:drug effects*; D002738:Chloroquine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D002784:Cholesterol / Q000378:metabolism*; D002908:Chronic Disease; D005260:Female; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D000962:Antimalarials; D006454:Hemoglobins; D002738:Chloroquine; D002784:Cholesterol